A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma

Abstract This phase II clinical trial aimed to evaluate the efficacy and safety of the combination therapy of bendamustine, cytarabine, and rituximab (BRAC) in patients with relapsed or refractory follicular lymphoma (FL) or mantle cell lymphoma (MCL). Thirteen patients were enrolled and received a...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Nobuhiko Nakamura, Senji Kasahara, Junichi Kitagawa, Hiroshi Nakamura, Michio Sawada, Kenji Fukuno, Yuhei Shibata, Yuto Kaneda, Takeshi Hara, Nobuhiro Kanemura, Hisashi Tsurumi, Masahito Shimizu
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2022-02-01
סדרה:	Experimental Hematology & Oncology
נושאים:	Follicular lymphoma Mantle cell lymphoma Bendamustine Rituximab Cytarabine
גישה מקוונת:	https://doi.org/10.1186/s40164-022-00264-3
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!